Journal of Oncology / 2009 / Article / Tab 4

Review Article

Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers

Table 4

Selected clinical trials of panitumumab. mCRC, metastatic colorectal cancer; BSC, best supportive care; OS, overall survival; PFS, progression free survival; ORR, overall response rate; SD, stable disease; FOLFOX, 5 Flourouracil/Folinic Acid and oxaliplatin; FOLFIRI, 5 Flourouracil/Folinic Acid and Irinotecan.

MalignancyRegimenNumber of patientsResultsComments

mCRCPanitumumab vs. BSC [35]463 pts Pts with progression after standard chemotherapyPanitumumab: ORR (10%) PFS (13.8 weeks) BSC: ORR (0%) PFS (8.5 weeks)No significant improvement in OS

mCRCPanitumumab monotherapy after disease progression with BSC [36]176 pts Pts with progression of disease in BSC arm of Panitumumab vs. BSC trial [35]Panitumumab: ORR (11.6%) SD (33%) Median PFS of 9.4 weeksResults comparable to initial study

mCRCFOLFOX or FOLFIRI with Bevacizumab +/ Panitumumab [37]823 ptsFOLFOX, Bevacizumab, Panitumumab: Median PFS (9.5 mo) OS (19.3 mo) FOLFOX, Bevacizumab: Median PFS (11 mo) OS (20.6 mo)Panitumumab in combination with FOLFOX and bevacizumab was associated with a shorter PFS and increased toxicity

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.